Drug Trial Radar · NCT01218659
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Nov 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Sep 8, 2011
Primary completion
May 27, 2014
Study completion May 28, 2015
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to compare the efficacy and safety of migalastat and enzyme replacement therapy (ERT) in male and female participants with Fabry disease who are currently receiving ERT and who have an alpha galactosidase-A (α Gal-A) mutation that is amenable to migalastat, based on the clinical trial human embryonic kidney cell (HEK) assay.
Conditions
- Fabry Disease
Interventions
migalastat hydrochlorideDrug
150-mg capsule administered orally QOD
agalsidaseBiological
Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration RateTime frame: Baseline to Month 18
- Annualized Rate Of Change From Baseline To Month 18 In eGFRTime frame: Baseline to Month 18
Locations
25 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Aurora, Colorado
Site not named
Decatur, Georgia
Site not named
Grand Rapids, Michigan
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Fairfax, Virginia
Site not named
Milwaukee, Wisconsin
Site not named
Parkville, Victoria, Australia
Site not named
Perth, Western Australia, Australia
Site not named
Vienna, Austria
Site not named
Edegem, Belgium
Site not named
São Paulo, Brazil
Site not named
Copenhagen, Denmark
Site not named
Garches, France
Site not named
Lille, France
Site not named
Florence, Italy
Site not named
Niigata, Japan
Site not named
Osaka, Japan
Site not named
Osaka, Japan
Site not named
Tokyo, Japan
Site not named
Cambridge, United Kingdom
Site not named
London, United Kingdom
Site not named
London, United Kingdom
Site not named
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.